APA (7th ed.) Citation

Xu, S., Pang, Q., Wei, M., Liu, D., Yuan, D., Bai, T., . . . Wu, F. (2025). Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors. Frontiers in cellular and infection microbiology, 15, 1598193. https://doi.org/10.3389/fcimb.2025.1598193

Chicago Style (17th ed.) Citation

Xu, Shaowei, Qingqing Pang, Meng Wei, Danxi Liu, Du Yuan, Tao Bai, Xiaobo Wang, Zhihong Tang, and Feixiang Wu. "Postoperative Hepatitis B Virus Reactivation and Its Impact on Survival in HBV-related Hepatocellular Carcinoma Patients Undergoing Conversion Therapy with Interventional Therapy Combined with Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors." Frontiers in Cellular and Infection Microbiology 15 (2025): 1598193. https://doi.org/10.3389/fcimb.2025.1598193.

MLA (9th ed.) Citation

Xu, Shaowei, et al. "Postoperative Hepatitis B Virus Reactivation and Its Impact on Survival in HBV-related Hepatocellular Carcinoma Patients Undergoing Conversion Therapy with Interventional Therapy Combined with Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors." Frontiers in Cellular and Infection Microbiology, vol. 15, 2025, p. 1598193, https://doi.org/10.3389/fcimb.2025.1598193.